Successful management of Barth syndrome: a systematic review highlighting the importance of a flexible and multidisciplinary approach

This review describes and summarizes the available evidence related to the treatment and management of Barth syndrome. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards were used to identify articles published between December 2004 and January 2015. The Cochrane Population, Intervention, Control, Outcome, Study Design (PICOS) approach was used to guide the article selection and evaluation process. Of the 128 articles screened, 28 articles matched the systematic review inclusion criteria. The results of this review indicate the need for a flexible and multidisciplinary approach to manage the symptoms most commonly associated with Barth syndrome. It is recommended that a comprehensive care team should include individuals with Barth syndrome, their family members and caregivers, as well as medical, rehabilitative, nutritional, psychological, and educational professionals. The evidence for specific treatments, therapies, and techniques for individuals with Barth syndrome is currently lacking in both quality and quantity.

[1]  M. L. Greenberg,et al.  Cardiolipin remodeling: a regulatory hub for modulating cardiolipin metabolism and function , 2016, Journal of Bioenergetics and Biomembranes.

[2]  B. Byrne,et al.  Endurance training ameliorates complex 3 deficiency in a mouse model of Barth syndrome , 2015, Journal of Inherited Metabolic Disease.

[3]  J. Mayr.  Lipid metabolism in mitochondrial membranes , 2015, Journal of Inherited Metabolic Disease.

[4]  S. Heales,et al.  Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype , 2014, Journal of Inherited Metabolic Disease.

[5]  S. Debnath,et al.  Mis-sesnse mutations in Tafazzin (TAZ) that escort to mild clinical symptoms of Barth syndrome is owed to the minimal inhibitory effect of the mutations on the enzyme function: In-silico evidence , 2014, Interdisciplinary Sciences: Computational Life Sciences.

[6]  G. Hatch,et al.  Cardiolipin metabolism and the role it plays in heart failure and mitochondrial supercomplex formation. , 2014, Cardiovascular & hematological disorders drug targets.

[7]  A. Malhotra,et al.  Pharmacogenomic considerations in the treatment of the pediatric cardiomyopathy called Barth syndrome. , 2014, Recent Patents on Biotechnology.

[8]  Robert Zweigerdt,et al.  Your heart on a chip: iPSC-based modeling of Barth-syndrome-associated cardiomyopathy. , 2014, Cell stem cell.

[9]  F. Casas,et al.  Impact of high dietary lipid intake and related metabolic disorders on the abundance and acyl composition of the unique mitochondrial phospholipid, cardiolipin , 2014, Journal of Bioenergetics and Biomembranes.

[10]  T. Kamp,et al.  Cardiomyopathy, mitochondria and Barth syndrome: iPSCs reveal a connection , 2014, Nature Medicine.

[11]  R. Kelley,et al.  Clinical laboratory studies in Barth Syndrome. , 2014, Molecular genetics and metabolism.

[12]  A. Plebani,et al.  Cardiomyopathy in a male patient with neutropenia and growth delay , 2014, Italian Journal of Pediatrics.

[13]  Rolf Wynn,et al.  The clinical case report: a review of its merits and limitations , 2014, BMC Research Notes.

[14]  M. L. Greenberg,et al.  The functions of cardiolipin in cellular metabolism-potential modifiers of the Barth syndrome phenotype. , 2014, Chemistry and physics of lipids.

[15]  J. Finsterer,et al.  Unclassified cardiomyopathies in neuromuscular disorders , 2013, Wiener Medizinische Wochenschrift.

[16]  P. Oliveira,et al.  Mitochondrial membrane lipid remodeling in pathophysiology: a new target for diet and therapeutic interventions. , 2013, Progress in lipid research.

[17]  S. Heales,et al.  Diagnosis of Barth syndrome using a novel LC-MS/MS method for leukocyte cardiolipin analysis , 2013, Journal of Inherited Metabolic Disease.

[18]  R. Wanders,et al.  Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation. , 2013, Biochimica et biophysica acta.

[19]  F. Rivier,et al.  Natural history of Barth syndrome: a national cohort study of 22 patients , 2013, Orphanet Journal of Rare Diseases.

[20]  M. Seong,et al.  A Novel Mutation of the TAZ Gene in Barth Syndrome: Acute Exacerbation after Contrast-Dye Injection , 2013, Journal of Korean medical science.

[21]  Z. Khuchua,et al.  Advances in the understanding of Barth syndrome , 2013, British journal of haematology.

[22]  F. Lamari,et al.  Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases , 2013, Journal of Inherited Metabolic Disease.

[23]  A. Giardini,et al.  Successful mechanical circulatory support for 251 days in a child with intermittent severe neutropenia due to Barth syndrome , 2013, Pediatric transplantation.

[24]  E. Bertini,et al.  New clinical and molecular insights on Barth syndrome , 2013, Orphanet Journal of Rare Diseases.

[25]  S. Claypool,et al.  Seven functional classes of Barth syndrome mutation. , 2013, Human molecular genetics.

[26]  K. Kokoszyńska,et al.  Left ventricular noncompaction (LVNC) and low mitochondrial membrane potential are specific for Barth syndrome , 2013, Journal of Inherited Metabolic Disease.

[27]  B. Funke,et al.  NGS identifies TAZ mutation in a family with X-linked dilated cardiomyopathy , 2013, BMJ Case Reports.

[28]  J. Finsterer,et al.  Haematological features in Barth syndrome , 2013, Current opinion in hematology.

[29]  B. Byrne,et al.  Substrate metabolism during basal and hyperinsulinemic conditions in adolescents and young-adults with Barth syndrome , 2013, Journal of Inherited Metabolic Disease.

[30]  B. Byrne,et al.  The Barth Syndrome Registry: Distinguishing disease characteristics and growth data from a longitudinal study , 2012, American journal of medical genetics. Part A.

[31]  J. Platt,et al.  Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle. , 2012, Molecular genetics and metabolism.

[32]  S. Reynolds,et al.  A mixed‐methods investigation of sensory response patterns in Barth syndrome: A clinical phenotype? , 2012, American journal of medical genetics. Part A.

[33]  C. Rakovski,et al.  Higher IL-6 and IL6:IGF Ratio in Patients with Barth Syndrome , 2012, Journal of Inflammation.

[34]  M. Mazzocco,et al.  Emergence and Nature of Mathematical Difficulties in Young Children with Barth Syndrome , 2012, Journal of developmental and behavioral pediatrics : JDBP.

[35]  Yao-Hsu Yang,et al.  Clinical manifestations and outcomes of pediatric chronic neutropenia. , 2012, Journal of the Formosan Medical Association = Taiwan yi zhi.

[36]  J. Towbin,et al.  Left Ventricular Noncompaction Cardiomyopathy in Barth Syndrome: An Example of an Undulating Cardiac Phenotype Necessitating Mechanical Circulatory Support as a Bridge to Transplantation , 2012, Pediatric Cardiology.

[37]  D. Dale,et al.  The cellular and molecular mechanisms for neutropenia in Barth syndrome , 2012, European journal of haematology.

[38]  E. Gottlieb,et al.  The music of lipids: How lipid composition orchestrates cellular behaviour , 2012, Acta oncologica.

[39]  F. Ichida,et al.  Differing clinical courses and outcomes in two siblings with Barth syndrome and left ventricular noncompaction , 2012, European Journal of Pediatrics.

[40]  K. Vesela,et al.  Neonatal onset of mitochondrial disorders in 129 patients: clinical and laboratory characteristics and a new approach to diagnosis , 2012, Journal of Inherited Metabolic Disease.

[41]  G. Hatch,et al.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders , 2012, Journal of Lipid Research.

[42]  I. Nishino,et al.  Barth syndrome diagnosed in the subclinical stage of heart failure based on the presence of lipid storage myopathy and isolated noncompaction of the ventricular myocardium , 2011, European Journal of Pediatrics.

[43]  B. Byrne,et al.  Impaired cardiac reserve and severely diminished skeletal muscle O₂ utilization mediate exercise intolerance in Barth syndrome. , 2011, American journal of physiology. Heart and circulatory physiology.

[44]  B. Byrne,et al.  Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency. , 2011, Human gene therapy.

[45]  Xianlin Han,et al.  Barth syndrome mutations that cause tafazzin complex lability , 2011, The Journal of cell biology.

[46]  Saskia B Wortmann,et al.  Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway , 2011, European Journal of Human Genetics.

[47]  J. Wansapura,et al.  Cardiac and Skeletal Muscle Defects in a Mouse Model of Human Barth Syndrome* , 2010, The Journal of Biological Chemistry.

[48]  F. Ali,et al.  Barth Syndrome: An X-linked Cardiomyopathy with a Novel Mutation , 2010, Indian journal of pediatrics.

[49]  R. Wanders,et al.  Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth , 2010, Prenatal diagnosis.

[50]  J. Towbin.  Left ventricular noncompaction: a new form of heart failure. , 2010, Heart failure clinics.

[51]  J. Finsterer,et al.  Neuromuscular disorders in left ventricular hypertrabeculation/noncompaction. , 2010, Current pharmaceutical design.

[52]  T. Langer,et al.  A mitochondrial phosphatase required for cardiolipin biosynthesis: the PGP phosphatase Gep4 , 2010, The EMBO journal.

[53]  G. Hatch,et al.  Reduction in cholesterol synthesis in response to serum starvation in lymphoblasts of a patient with Barth syndrome. , 2010, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[54]  H. Kanegane,et al.  Gonadal mosaicism of a TAZ (G4.5) mutation in a Japanese family with Barth syndrome and left ventricular noncompaction. , 2010, Molecular genetics and metabolism.

[55]  Stephan Kutik,et al.  Mitochondrial Cardiolipin Involved in Outer-Membrane Protein Biogenesis: Implications for Barth Syndrome , 2009, Current Biology.

[56]  R. Wanders,et al.  The enigmatic role of tafazzin in cardiolipin metabolism. , 2009, Biochimica et biophysica acta.

[57]  R. Newbury-Ecob,et al.  Dysmorphology of Barth syndrome , 2009, Clinical dysmorphology.

[58]  A. Vazeou,et al.  A novel mutation in the G4.5 (TAZ) gene in a Greek patient with Barth syndrome. , 2009, Blood cells, molecules & diseases.

[59]  J. Towbin,et al.  A novel Alu‐mediated Xq28 microdeletion ablates TAZ and partially deletes DNL1L in a patient with Barth syndrome , 2009, American journal of medical genetics. Part A.

[60]  R. Wanders,et al.  Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome. , 2009, Analytical biochemistry.

[61]  B. Byrne,et al.  Psychosocial Functioning in Youth With Barth Syndrome , 2009, Children's health care : journal of the Association for the Care of Children's Health.

[62]  E. Lesnefsky,et al.  Cardiolipin Remodeling in the Heart , 2009, Journal of cardiovascular pharmacology.

[63]  M. Schlame,et al.  Role of calcium-independent phospholipase A2 in the pathogenesis of Barth syndrome , 2009, Proceedings of the National Academy of Sciences.

[64]  J. Finsterer.  Cardiogenetics, Neurogenetics, and Pathogenetics of Left Ventricular Hypertrabeculation/Noncompaction , 2009, Pediatric Cardiology.

[65]  T. Kuijpers,et al.  Mitochondrial defects lie at the basis of neutropenia in Barth syndrome , 2009, Current opinion in hematology.

[66]  J. Loo,et al.  Correction for The Cardiolipin Transacylase, Tafazzin, Associates with Two Distinct Respiratory Components Providing Insight into Barth Syndrome , 2008, Molecular biology of the cell.

[67]  R. Wanders,et al.  Cardiolipin provides an essential activating platform for caspase-8 on mitochondria , 2008, The Journal of cell biology.

[68]  Robert T. Sweeney,et al.  Cardiomyopathy of unknown etiology: Barth syndrome unrecognized. , 2008, Congenital heart disease.

[69]  A. Chang,et al.  Cardiomyopathy in a child with neutropenia and motor delay , 2008, Current opinion in pediatrics.

[70]  W. Hwu,et al.  Mitral annuloplasty in an infant with Barth syndrome and severe mitral insufficiency: first case report and determination of annular diameter. , 2008, The Journal of thoracic and cardiovascular surgery.

[71]  E. Basargina,et al.  Gene symbol: TAZ. Disease: Barth syndrome. , 2008, Human Genetics.

[72]  J. Finsterer,et al.  Atrial fibrillation/flutter in myopathies. , 2008, International Journal of Cardiology.

[73]  Y. Chien,et al.  Acute metabolic decompensation and sudden death in Barth syndrome: report of a family and a literature review , 2008, European Journal of Pediatrics.

[74]  Ewa Moric‐Janiszewska,et al.  Genetic Heterogeneity of Left‐ventricular Noncompaction Cardiomyopathy , 2008, Clinical cardiology.

[75]  R. Houtkooper,et al.  Cardiolipin, the heart of mitochondrial metabolism , 2008, Cellular and Molecular Life Sciences.

[76]  R. Wanders,et al.  Bloodspot assay using HPLC-tandem mass spectrometry for detection of Barth syndrome. , 2008, Clinical chemistry.

[77]  J. Finsterer,et al.  Prevalence of Barth syndrome in adult left ventricular hypertrabeculation / noncompaction , 2008, Scandinavian cardiovascular journal : SCJ.

[78]  J. Finsterer,et al.  Primary myopathies and the heart , 2008, Scandinavian cardiovascular journal : SCJ.

[79]  E. Arbustini,et al.  Noncompaction of the left ventricle: primary cardiomyopathy with an elusive genetic etiology , 2007, Current opinion in pediatrics.

[80]  J. Finsterer,et al.  Hematological Manifestations of Primary Mitochondrial Disorders , 2007, Acta Haematologica.

[81]  Eloisa Arbustini,et al.  Barth syndrome associated with compound hemizygosity and heterozygosity of the TAZ and LDB3 genes , 2007, American journal of medical genetics. Part A.

[82]  M. Elliott,et al.  Successful cardiac transplantation in Barth syndrome – single‐centre experience of four patients , 2007, Pediatric transplantation.

[83]  V. Funanage,et al.  Multiple transmissions of Barth syndrome through an oocyte donor with a de novo TAZ mutation. , 2007, Fertility and sterility.

[84]  M. Mazzocco,et al.  Barth Syndrome Is Associated with a Cognitive Phenotype , 2007, Journal of developmental and behavioral pediatrics : JDBP.

[85]  R Brian Haynes,et al.  Evidence based medicine: what it is and what it isn't. 1996. , 2007, Clinical orthopaedics and related research.

[86]  M. Schlame,et al.  Barth syndrome, a human disorder of cardiolipin metabolism , 2006, FEBS letters.

[87]  D. Thorburn,et al.  Monolysocardiolipin in cultured fibroblasts is a sensitive and specific marker for Barth Syndrome Published, JLR Papers in Press, July 27, 2006. , 2006, Journal of Lipid Research.

[88]  L. Barness,et al.  Festschrift for Dr. John M. Opitz: Pathogenesis of cardiac conduction disorders in children genetic and histopathologic aspects , 2006, American journal of medical genetics. Part A.

[89]  S. Kasner,et al.  Stroke Associated With Barth Syndrome , 2006, Journal of child neurology.

[90]  M. Lazarou,et al.  Mitochondrial respiratory chain supercomplexes are destabilized in Barth Syndrome patients. , 2006, Journal of molecular biology.

[91]  D. Toniolo,et al.  Barth syndrome presenting with acute metabolic decompensation in the neonatal period , 2006, Journal of Inherited Metabolic Disease.

[92]  B. Byrne,et al.  Cardiac and Clinical Phenotype in Barth Syndrome , 2006, Pediatrics.

[93]  J. McCaffery,et al.  Mitochondrial mislocalization and altered assembly of a cluster of Barth syndrome mutant tafazzins , 2006, The Journal of cell biology.

[94]  J. Finsterer,et al.  Neuromuscular implications in left ventricular hypertrabeculation/noncompaction. , 2006, International journal of cardiology.

[95]  P. Fernhoff,et al.  X‐linked fetal cardiomyopathy caused by a novel mutation in the TAZ gene , 2006, Prenatal diagnosis.

[96]  G. Hatch,et al.  Cardiolipin metabolism and Barth Syndrome. , 2006, Progress in lipid research.

[97]  B. Byrne,et al.  GRIP STRENGTH IN A POPULATION OF BOYS WITH BARTH SYNDROME , 2006 .

[98]  B. Byrne,et al.  Ventricular Arrhythmia in the X-linked Cardiomyopathy Barth Syndrome , 2005, Pediatric Cardiology.

[99]  S. Dimauro,et al.  The expanding phenotype of mitochondrial myopathy , 2005, Current opinion in neurology.

[100]  P. Rehling,et al.  Taz1, an outer mitochondrial membrane protein, affects stability and assembly of inner membrane protein complexes: implications for Barth Syndrome. , 2005, Molecular biology of the cell.

[101]  A. Munnich,et al.  Monolysocardiolipins accumulate in Barth syndrome but do not lead to enhanced apoptosis Published, JLR Papers in Press, April 1, 2005. DOI 10.1194/jlr.M500056-JLR200 , 2005, Journal of Lipid Research.

[102]  M. Schlame,et al.  Characterization of lymphoblast mitochondria from patients with Barth syndrome , 2005, Laboratory Investigation.

[103]  I. Gonzalez.  Barth syndrome: TAZ gene mutations, mRNAs, and evolution , 2005, American journal of medical genetics. Part A.

[104]  K. Fujieda,et al.  Hypomagnesemia in a Patient with Barth Syndrome , 2005, Journal of Pediatric Endocrinology & Metabolism (JPEM).

[105]  Toshio Miyawaki,et al.  Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. , 2005, Molecular genetics and metabolism.

[106]  J. Huhta,et al.  CLINICOPATHOLOGIC CONFERENCE: BARTH SYNDROME , 2005, Fetal and pediatric pathology.

[107]  D. Sackett,et al.  Evidence based medicine: what it is and what it isn't , 1996, BMJ.

[108]  R. Hitchings.  Mitochondrial myopathies. , 1989, BMJ.

[109]  J. Berden,et al.  An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes , 1983, Journal of the Neurological Sciences.

[110]  Susan M Kirwin,et al.  Tafazzin splice variants and mutations in Barth syndrome. , 2014, Molecular genetics and metabolism.

[111]  M. Tesařová,et al.  Novel mutations in the TAZ gene in patients with Barth syndrome. , 2013, Prague medical report.

[112]  V. Kimonis,et al.  A Novel Exonic Splicing Mutation in the TAZ (G4.5) Gene in a Case with Atypical Barth Syndrome. , 2013, JIMD reports.

[113]  M. Sabater-Molina,et al.  Barth syndrome in adulthood: a clinical case. , 2013 .

[114]  Amit S. Joshi.  Identification of cellular functions of cardiolipin as physiological modifiers of barth syndrome , 2012 .

[115]  P. Griač,et al.  Phospholipid transport and remodeling in health and disease. , 2011, General physiology and biophysics.

[116]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[117]  D. Stokes,et al.  Comparison of lymphoblast mitochondria from normal subjects and patients with Barth syndrome using electron microscopic tomography , 2007, Laboratory Investigation.

[118]  G. Sparagna,et al.  Role of cardiolipin alterations in mitochondrial dysfunction and disease. , 2007, American journal of physiology. Cell physiology.

[119]  Guiling Li.  The role of mitochondrial anionic phospholipids in signaling pathways and essential functions , 2007 .

[120]  L. G. Bell,et al.  University of Manitoba , 2018, Radiocarbon.

[121]  S. Nancarrow,et al.  Assessing the implementation process and outcomes of newly introduced assistant roles: a qualitative study to examine the utility of the Calderdale Framework as an appraisal tool , 2012, Journal of multidisciplinary healthcare.

[122]  N. Nitta,et al.  submit your manuscript | www.dovepress.com , 2022 .